Sinomab Bio B

Sinomab Bio B, a Pharmaceutical Preparation Manufacturing company headquartered in Hong Kong, reported total Scope 1, 2, and 3 emissions of approximately 358,460 kg CO2e in 2025. This figure comprises about 2,290 kg CO2e from Scope 1, 333,610 kg CO2e from Scope 2, and 22,560 kg CO2e from Scope 3 emissions. In 2024, the company's total emissions were approximately 1,347,510 kg CO2e, with Scope 1 at about 219,190 kg CO2e, Scope 2 at roughly 1,070,810 kg CO2e, and Scope 3 at around 57,510 kg CO2e. For 2023, Sinomab Bio B reported total emissions of approximately 2,723,220 kg CO2e, including Scope 1 emissions of about 31,960 kg CO2e, Scope 2 emissions of roughly 2,615,440 kg CO2e, and Scope 3 emissions of approximately 75,820 kg CO2e.

Looking back, in 2022, total emissions stood at around 4,618,000 kg CO2e (Scope 1: 58,000 kg CO2e, Scope 2: 4,537,000 kg CO2e, Scope 3: 23,000 kg CO2e). In 2021, the company disclosed approximately 4,695,590 kg CO2e in combined Scope 1 and 2 emissions, with Scope 1 at about 69,010 kg CO2e and Scope 2 at roughly 4,626,580 kg CO2e. For 2020, combined Scope 1 and 2 emissions were approximately 2,042,372.3 kg CO2e (Scope 1: 5,344.3 kg CO2e, Scope 2: 2,037,028 kg CO2e). In 2019, combined Scope 1 and 2 emissions were approximately 1,679,600.4 kg CO2e (Scope 1: 6,802.8 kg CO2e, Scope 2: 1,672,797.6 kg CO2e).

Sinomab Bio B has set near-term net-zero targets to reduce its Scope 1 emissions to near zero by 2025 and its Scope 2 emissions to near zero by 2025, with both targets starting in 2023.